EBS Emergent Bio Expected net earnings per share growth this year

Emergent BioSolutions (EBS) is developing biodefense solutions through government alliances and the acquisition of manufacturing plants. The YoY EPS trend reflects current margins and liquidity risks, where -81.60 represents the current level of the metric. Management is currently reducing debt and focusing on the commercialization of antidotes, while its status as a strategic vaccination supplier protects the company from default.

Earnings per share growth in current year: Emergent Corp (EBS) for 07/04/2022 - 11/11/2026

Analytical breakdowns and data insights for company Emergent BioSolutions (EBS)

- market value and analyst target forecast:

Stock Price Emergent BioSolutions Inc|EBS - Price Target Chart

- market capitalization data:

Market Capitalization Emergent Bio|EBS - Enterprise Value

- shareholders' equity book value data:

Net Asset Value per Share Emergent BioSolutions|EBS - Company Book Value|Market Cap to Net Assets Ratio emergentbiosolutions.com|EBS - Company Total Assets

- debt burden and liquidity indicators:

- company profitability and valuation multiples indicators:

EBS - Net Income|Future Net Profit Emergent BioSolutions|EBS - Price to Earnings Ratio|Future Price to Earnings Multiple Emergent Bio|EBS - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Emergent Bio|EBS - Operating profit EBITDA|Net earnings per share for the last four quarters Emergent BioSolutions|EBS - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months emergentbiosolutions.com|EBS - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Emergent BioSolutions

Fundamental valuation:EBS (Emergent BioSolutions Inc)

Signature product of emergentbiosolutions.com

This indicator captures the year-over-year dynamics of earnings per share, transforming discrete quarterly reports into a continuous curve of fundamental growth. By analyzing the annual percentage growth of net earnings per share, an investor can discern the effectiveness of the Emergent BioSolutions (EBS) portfolio restructuring and the management's success in optimizing production costs amid the struggle with a debt crisis.

Direct competitors

Gilead (GILD) - Earnings growth in current year|Earnings per share growth in current year Cidara Therapeutics|Novavax Pharma (NVAX) - Expected net earnings per share growth this year|Earnings growth in current year CVAC|VALN - Earnings per share growth rate in current year|Earnings per share growth in current year Vir Biotechnology VIR|SIGA - Net earnings per share growth this year|Atea Pharmaceuticals Inc - Earnings growth in current year|Earnings per share growth rate in current year Invivyd, Inc.|Enanta Pharmaceuticals (ENTA) - Earnings per share growth in current year|inovio.com - Earnings per share increase in current year|HLVX (HilleVax) - Earnings growth in current year|KLRS - Net earnings per share change in current year|Earnings growth in current year DYAI|NNVC - Earnings per share growth rate in current year|Earnings per share growth in current year Talphera, Inc. TLPH|COCP: Earnings per share growth this year|TRAW: Net earnings per share growth this year|Dogwood Therapeutics, Inc. - Net earnings per one share growth for the current year|QLGN (Qualigen) - Net earnings per share growth this year|AlloVir - Earnings per share increase in current year|VBIV (VBI Vaccines, Inc.) - Earnings growth in current year|Earnings per share growth in current year VIRI|Earnings growth in current year VXRT